

GLAXOSMITHKLINE PLC

Form 6-K

November 04, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 04 November 2016

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- |    |                                    |                           |
|----|------------------------------------|---------------------------|
| a) | Name                               | Dr M M Slaoui             |
| b) | Position/status                    | Chairman, Global Vaccines |
| c) | Initial notification/<br>amendment | Initial notification      |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |    |      |                      |
|----|------|----------------------|
| a) | Name | GlaxoSmithKline plc  |
| b) | LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |    |   |   |
|----|---|---|
| a) | Description of the financial instrument | GlaxoSmithKline plc<br>American Depositary Shares ('ADSs')  |
|    |   | ISIN: US37733W1053  |
| b) | Nature of the transaction               | An increase of 22 ADS following the notional allocation of ADSs on 3 November 2016, at a price of \$38.74 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan. |
| c) | Price(s) and volume(s)                  | Price(s)      Volume(s)<br>\$38.74          22  |
|    | Aggregated information                  |   |
| d) | Aggregated volume Price                 | n/a (single transaction)  |
| e) | Date of the transaction                 | 2016-11-03  |
| f) | Place of the transaction                | n/a   |

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Dr K Slaoui
  - b) Position/status PCA of Dr M M Slaoui  
(Chairman, Global Vaccines)
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument GlaxoSmithKline plc  
American Depositary Shares  
(‘ADSs’)
  - b) Nature of the transaction ISIN: US37733W1053  
  
An increase of 3 ADS following the notional allocation of ADSs on 3 November 2016, at a price of \$38.74 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
  - c) Price(s) and volume(s) Price(s)      Volume(s)  
\$38.74          3
  - d) Aggregated information n/a (single transaction)
  - e) Date of the transaction Aggregated volume Price  
2016-11-03
  - f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: November 04, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc